Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by University of California, Davis
Sponsor:
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
University of California, Davis
ClinicalTrials.gov Identifier:
NCT01736943
First received: November 26, 2012
Last updated: August 30, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)